ホーム › 乳がん › アラバマ州 › Birmingham
Birmingham、ALにおける乳がんの臨床試験
Birminghamとその周辺地域（約30マイル以内）の拠点で、乳がんに関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Central Alabama Research, Birmingham
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
被験者募集中第2相
- Alabama Oncology, Birmingham
PRE-ISPY Phase I/II Oncology Platform Program
被験者募集中第1/2相
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
被験者募集中第2相
- University of Alabama at Birmingham, Birmingham
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
被験者募集中第1相
- University of Alabama At Birmingham Hospital, Birmingham
Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
被験者募集中
- The Kirklin Clinic, Birmingham
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
被験者募集中第1/2相
- University of Alabama at Birmingham, Birmingham
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
被験者募集中第2相
- University of Alabama at Birmingham, Birmingham
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
被験者募集中健康なボランティア歓迎
- University of Alabama at Birmingham, Birmingham
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- University of Alabama Birmingham, Birmingham
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
被験者募集中観察研究
- Birmingham Hematology Associates, Birmingham
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
被験者募集中第2相
- University of Alabama, Birmingham
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
被験者募集中健康なボランティア歓迎
- University of Alabama, Birmingham, Birmingham
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
被験者募集中第1相
- Uni of Alabama at Birmingham, Birmingham
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
被験者募集中
- The University of Alabama, Birmingham
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
被験者募集中第2相
- University of Alabama at Birmingham, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
被験者募集中
- University of Alabama at Birmingham, Birmingham
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
被験者募集中第2相
- University of Alabama at Birmingham, Birmingham
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
被験者募集中早期第1相
- The Kirklin Clinic, Birmingham
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
被験者募集中第2相
- University of Alabama Birmingham, Birmingham
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
被験者募集中
- The University of Alabama at Birmingham, Birmingham
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
被験者募集中
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Birmingham
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Birminghamにおける他の研究
- がん（全種類）31件の研究
- 卵巣がん23件の研究
- 肥満症23件の研究
- 非小細胞肺癌22件の研究
- 急性骨髄性白血病21件の研究
- 多発性骨髄腫18件の研究
- COPD17件の研究
- 心血管疾患17件の研究
- 2型糖尿病16件の研究
- 子宮内膜がん16件の研究
- 過体重16件の研究
- 嚢胞性線維症16件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。